The Next-Generation Implantable Cardioverter Defibrillator:

Meaningful innovation in the $5 billion ICD market has stagnated. North American EP Technology is focused on addressing critical unmet needs and creating a new generation of ICDs. We have assembled an impressive leadership team with deep medical device business and technical experience.

About The Company

Addressing Unmet Needs. Driving Clinical Value.

North American EP Technology is committed to significantly improving patient outcomes in ICD patients. Extensive clinical evidence shows that ICDs save lives, yet the therapy is still underutilized after 30+ years on the market. We have innovation to address long-standing, critical unmet needs that improve clinical outcomes, reduce the cost of the therapy, and increase access to this lifesaving therapy.


Accomplishments to date include a strong and growing patent portfolio and proprietary, patented technical solution confirmed by two successful preclinical studies.

Leadership Team

Yanhui Li, MD, PhD / Chairman, CEO

Dr. Yanhui Li, MD, PhD, is a chief cardiologist and practicing cardiac electrophysiologist with over 30 years of clinical experience. He is committed to improving patient outcomes in all areas of electrophysiology, with a deep focus on implantable cardioverter defibrillators (ICDs).

Dr. Li was a visiting scholar at the University of Minnesota School of Medicine in 2009 and again from 2016 to 2018, all focused on improving ICD patient outcomes. He has translated this experience into developing a new generation of substernal implantable ICDs, with more than ten patents and patent applications in China and the US.

Dr. Li is extensively published in China, with more than 110 peer-reviewed journal articles in electrophysiology. He has also contributed to more than nine cardiology textbooks. Dr. Li’s expertise is recognized through his roles as a member of the Standing Committee of the Cardiovascular Branch of the China Medical Promotion Association, an editorial board member of the Journal of Cardiovascular Disease Research, a member of the Medical Education Working Committee of the Chinese Heart Rhythm Society, a member of Antiarrhythmic Drug Therapy Working Committee of Chinese Heart Rhythm Society, and editorial board member of Chinese Journal of Emergency Medicine.

Dr. Li graduated from Hebei Medical University and earned his PhD from Tsinghua University. He has been a licensed clinical physician in China since 1993. He was in the first cohort of trained electrophysiology interventional physicians in China engaged in clinical and research electrophysiology.

Dr. Li was a faculty member at Heart Center, Beijing Chaoyang Hospital, Capital University of Medical Science (2000 – 2010), Heart Center, the First Hospital of Tsinghua University (2010 – 2022), and Cardiovascular Disease Center, Suzhou Hospital, Nanjing Medical University (2022 – 2024). Dr. Li focused on clinical practice, bedside teaching, graduate teaching, and research, all forming his commitment to improving the ICD for improved patient outcomes and access.

Bob Gaskill / COO and CTO

Over 35 years in medical device product development at Guidant/Boston Scientific and Medtronic. Spanned numerous technologies, functions, and therapies. Led and was a member of teams that developed valuable technical improvements in implantable defibrillators, pacemakers, and patient management systems.  Bob is an accomplished medical device senior leader with a history of success in delivering value in product innovation.  He has deep experience in engineering leadership, product development, program management, strategic planning, team development, and managing complexity. BSEE from the University of Iowa. MBA from the University of St. Thomas.

Board Members

Paul McLean
  • CEO and Founder of ClarVista Medical, a VC funded ophthalmic device company that was acquired by Alcon in 2017
  • Executive leadership at Cardiva Medical that was acquired by Haemonetics in 2021
  • Guidant – Boston Scientific: executive level positions in Business Strategy, Upstream Marketing, Sales, Sales Operations, Market Research and Finance with large med tech companies in the U.S. and Europe
  • Deep expertise in Cardiac Rhythm Management
  • MBA from the University of Minnesota and Bachelor of Science in Electrical Engineering from Michigan State University.
Milton Morris, PhD
  • Currently serves on multiple boards of publicly traded companies and is a Trustee of Northwestern University
  • Chairman and CEO of Neuspera Medical – led this implantable neuromodulation therapy through multiple investment rounds, clinical studies, and ultimate regulatory approvals
  • Executive leadership at Cyberonics (now LivaNova)
  • Guidant – Boston Scientific – Global Arrhythmia Franchise Leader for pacing and implantable defibrillator markets
  • Deep implantable cardioverter defibrillator experience
  • Over 30 patents issued

Addressing Unmet Needs. Driving Clinical Value.


15 + 13 =